Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
received:
02
07
2022
accepted:
22
09
2022
pmc-release:
01
01
2024
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
31
1
2023
Statut:
ppublish
Résumé
To evaluate the association of number of radical hysterectomies performed per year in each center with disease-free survival and overall survival. We conducted an international, multicenter, retrospective study of patients previously included in the Surveillance in Cervical Cancer collaborative studies. Individuals with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB1-IIA1 cervical cancer who underwent radical hysterectomy and had negative lymph nodes at final histology were included. Patients were treated at referral centers for gynecologic oncology according to updated national and international guidelines. Optimal cutoffs for surgical volume were identified using an unadjusted Cox proportional hazard model, with disease-free survival as the outcome and defined as the value that minimizes the P-value of the split in groups in terms of disease-free survival. Propensity score matching was used to create statistically similar cohorts at baseline. A total of 2,157 patients were initially included. The two most significant cutoffs for surgical volume were identified at seven and 17 surgical procedures, dividing the entire cohort into low-volume, middle-volume, and high-volume centers. After propensity score matching, 1,238 patients were analyzed-619 (50.0%) in the high-volume group, 523 (42.2%) in the middle-volume group, and 96 (7.8%) in the low-volume group. Patients who underwent surgery in higher-volume institutions had progressively better 5-year disease-free survival than those who underwent surgery in lower-volume centers (92.3% vs 88.9% vs 83.8%, P=.029). No difference was noted in 5-year overall survival (95.9% vs 97.2% vs 95.2%, P=.70). Cox multivariable regression analysis showed that FIGO stage greater than IB1, presence of lymphovascular space invasion, grade greater than 1, tumor diameter greater than 20 mm, minimally invasive surgical approach, nonsquamous cell carcinoma histology, and lower-volume centers represented independent risk factors for recurrence. Surgical volume of centers represented an independent prognostic factor affecting disease-free survival. Increasing number of radical hysterectomies performed in each center every year was associated with improved disease-free survival.
Identifiants
pubmed: 36701621
doi: 10.1097/AOG.0000000000005026
pii: 00006250-202301000-00023
pmc: PMC10445691
mid: NIHMS1907518
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-214Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Financial Disclosure Henrik Falconer reports receiving payment from Intuitive Surgical and Surgical Science. The other authors did not report any potential conflicts of interest.
Références
Int J Gynecol Cancer. 2018 Jul;28(6):1226-1231
pubmed: 29958236
Br J Surg. 2005 Apr;92(4):389-402
pubmed: 15786424
Arch Gynecol Obstet. 2021 Aug;304(2):503-510
pubmed: 33483846
Gynecol Oncol. 2022 Feb;164(2):362-369
pubmed: 34955236
J Clin Oncol. 2000 Jun;18(11):2327-40
pubmed: 10829054
Gynecol Oncol. 2015 Dec;139(3):506-12
pubmed: 26177552
Medicine (Baltimore). 2018 Dec;97(49):e13445
pubmed: 30544427
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
Cancer Res Treat. 2021 Jan;53(1):243-251
pubmed: 33070554
Ann Surg Oncol. 2012 Mar;19(3):948-58
pubmed: 21989660
Ann Surg Oncol. 2017 Oct;24(11):3406-3412
pubmed: 28785898
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
Int J Gynecol Cancer. 2020 Jan;30(1):3-14
pubmed: 31900285
J Gynecol Oncol. 2021 Mar;32(2):e24
pubmed: 33470066
Facts Views Vis Obgyn. 2021 Sep;13(3):231-239
pubmed: 34555877
Int J Gynecol Cancer. 2022 Apr 4;32(4):494-501
pubmed: 34992130
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Obstet Gynecol. 2019 Jun;133(6):1086-1098
pubmed: 31135722
Eur J Cancer. 2021 Oct 16;158:111-122
pubmed: 34666213
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Obstet Gynecol. 2017 Sep;130(3):545-553
pubmed: 28796677
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Gynecol Oncol. 2021 Dec;163(3):583-592
pubmed: 34688503